[ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
Hallgren
Helena
H
Klinisk mikrobiologi och vårdhygien, Länssjukhuset, Halmstad. helena.hallgren@lthalland.se
Gustafsson
Ingegerd
I
Ripa
Torvald
T
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002511:Cephalosporins / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D024901:Drug Resistance, Multiple, Bacterial; D004755:Enterobacteriaceae / Q000187:drug effects / Q000201:enzymology; D004756:Enterobacteriaceae Infections / Q000188:drug therapy* / Q000382:microbiology; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology; D018440:beta-Lactam Resistance; D001618:beta-Lactamases / Q000378:metabolism*
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D001618:beta-Lactamases